Oncologic Biomarker Context for MHS
A biomarker is a measurable biological indicator. In cancer, biomarkers (like ctDNA, tumor size on imaging, or protein levels in blood) tell doctors how the cancer is responding to treatment. Paralle...
Explainers
Plain-English explanations of MEF2C research terms, concepts, and scientific mechanisms.
Common Terms
DNA base editing CRISPR AAV FDA approval Phase 2 Phase 3 Phase 4 Safety BBB Blood-Brain Barrier Microglia downregulated same subjects repeatedly over time directly from a patient before human trials begin same protein (CDK2) Why this is the gold standard: Global consortium: A compact polyadenylation signal A minimal promoter gene therapy Introns removed ERK MAPK MEK RAF RAS downstream MicroRNAs mRNA MUSC's RNA therapeutic approach Key precedent papers Why patents matter Dosing flexibility Manufacturing Regulatory familiarity Reversibility sponge Eventually bring the drug to market major milestone Navigate FDA approval Run clinical trials Seek additional funding startup company clinical readiness study Outcome measures Patient screening Regulatory groundwork Site selection Standardization private foundation Drug candidate Therapeutic candidate Discovery IND filing Lead optimization Phase 1 Preclinical testing Drug candidate: Investigational New Drug Lead New Drug Application Phase Natural history study Patient registry Dose-finding Pharmacokinetics Fat-soluble lipophilic substrate overdrive trim signal extracellular matrix metalloprotease scaffold protein de novo genetic counseling mutation foreman every cell Heterozygous Homozygous Adeno-Associated Virus delivery vehicle existing gene's message micro-RNA therapeutics new copy of the gene reprogrammed Why "ctDNA decreases" matters: AL-605 clinical trial Phase 1a Phase 1b repurposed super-filter completely different class of drug coding sequence Enhancers Polyadenylation signalsFDA Approval Precedent (for gene therapy)
The fact that seven AAV-based gene therapies have received FDA approval provides a regulatory pathway that the MEF2C gene therapy team can follow. FDA has extensive experience reviewing AAV gene thera...
Synthetic Biology (in gene therapy context)
Synthetic biology is the field of engineering biological components and systems that don't exist in nature. In gene therapy, this includes designing custom viral vectors, optimizing gene sequences for...
MEF2Cast (podcast details)
MEF2Cast is a podcast produced by the MEF2C community (particularly the US Foundation) that features interviews with researchers, families, and advocates. It serves as both an education tool for famil...
MEF2C Foundation Australia
Sean Rafferty and Claire Bothwell lead the Australian chapter of the MEF2C advocacy network. They've been active in the MEF2Cast podcast and have participated in international efforts alongside the UK...
MicroRNA (in the context of MHS RNA therapeutics)
MicroRNAs are tiny RNA molecules (about 22 nucleotides long) that regulate gene expression after transcription. They can bind to mRNA molecules and either block them from being translated into protein...
Germline Mosaicism (rare inheritance mechanism)
Germline mosaicism is a rare phenomenon where a parent has a mutation in some of their reproductive cells (sperm or eggs) but NOT in their body cells. This means the parent tested "normal" on standard...
CDK4/6 Inhibitor Resistance (oncology concept relevant to MHS)
When cancer cells are treated with CDK4/6 inhibitors, they eventually evolve resistance. One common mechanism is that cancer cells start relying more heavily on CDK2 instead of CDK4/6 — they "switch l...
KRAS Pathway / MAPK/ERK Signaling Pathway
First: What Even Is a "Pathway"?Cells aren't just blobs of jelly. They're incredibly organized — like a giant office building where every department needs to know what to do, when to do it, and who's ...
International Patent (WIPO/WO2026039331)
The WO2026039331 patent published through WIPO (World Intellectual Property Organization) covers the viral gene therapy approach for MEF2C. "WO" indicates a Patent Cooperation Treaty application, whic...
Gene Therapy Vector Optimisation (for AAV packaging)
The MEF2C gene is relatively large — about 12-13 kilobases (kb) of DNA. But the AAV vector can only carry about 4.7 kb of genetic material. So the UT Southwestern team had to "shrink" the MEF2C gene i...
MEF2C Hilfsorganisation (German MEF2C organization)
"Hilfsorganisation" means "help organization" or "support organization" in German. MEF2C Hilfsorganisation e.V. is the German patient advocacy group for MEF2C families. The "e.V." (eingetragener Verei...
Isogenic Cell Lines (in the context of the Hansen et al. paper)
Creating isogenic cell lines means taking one starting cell line and editing it so that one version has the mutation (MEF2C knockout) and the other doesn't (wild-type control). They're "identical twin...
Oncology / Solid Tumor (in CDK2 inhibitor context)
Oncology is the branch of medicine that deals with cancer. "Solid tumors" are cancers that form actual lumps or masses (as opposed to blood cancers like leukemia). Breast, ovarian, gastric, and other ...
CRISPR
What it means: CRISPR is a gene-editing tool that acts like molecular "scissors". It can find a specific DNA sequence and cut it, allowing researchers to delete, replace, or modify genes with extreme ...
Preclinical Update (in gene therapy context)
"Preclinical" means research done before human trials begin — in cell cultures (in vitro) and animal models (in vivo). A "preclinical update" means the researchers have completed early-stage animal or...
Patient-Derived (in cell biology context)
"Patient-derived" means cells, tissues, or samples that were taken directly from a patient (usually via biopsy or blood draw) and used in research. This is different from cancer cell lines (like HeLa ...
Longitudinal Data / Longitudinal Study
Longitudinal data is collected from the same subjects repeatedly over time — like taking photos of the same tree every year to watch it grow. This is different from a cross-sectional study, which look...
Drug Development Milestones (quick reference)
...
CARD11 (and why it matters)
CARD11 is a scaffold protein — it acts like a docking station that brings inflammatory signaling molecules together. When a microglial receptor detects a threat, CARD11 assembles the NF-κB inflammator...
ADAMDEC1 (and why it matters)
ADAMDEC1 is a metalloprotease — a protein-cutting enzyme that remodels the extracellular matrix (the structural scaffolding that holds brain cells in place). Think of it as the brain's "construction c...
Fc-gamma Receptor Signaling
Fc-gamma receptors are "antenna" proteins on microglia that detect antibodies attached to targets (like synaptic connections). When an antibody flags a synapse, the Fc-gamma receptor tells the microgl...
Microglial Synaptic Pruning
During brain development, the brain makes way more synaptic connections than it needs — like building more roads than necessary. Microglia (the brain's immune cells) act as "pruners" — they identify w...
Blood-Brain Barrier (BBB) Penetrance
The Blood-Brain Barrier (BBB) is like a military checkpoint between your bloodstream and your brain. It's made of tightly packed cells with no gaps — designed to keep toxins out. But it also keeps mos...
First-in-Human (FIH) Trial
This is the very first time a drug is given to people — never humans before, only animals (and cell cultures). It's essentially Phase 1a. The goals are: 1. Safety — does the drug cause unexpected side...
WIPO Patent Cooperation Treaty (PCT)
Think of the PCT as a "global patent application portal." Instead of filing separate patents in 100+ countries individually, inventors file one application that reserves their patent rights worldwide ...
Patient Registry vs. Natural History Study (clarification)
...
Drug Pipeline (in pharma context)
A "drug pipeline" is the entire journey a drug takes from the lab bench to the pharmacy shelf. Think of it as a factory assembly line: 1. Discovery → finding compounds that affect the target 2. Lead o...
Drug Candidate vs. Therapeutic Candidate
...
Behavioral Brain Research Foundation (BDRF)
The BDRF is a private foundation that funds neuroscience research. Their "Distinguished Investigative Grant" is a significant award given to researchers who have demonstrated exceptional promise in ad...
Clinical Readiness Study (vs. Clinical Trial)
A "clinical readiness study" is different from a full clinical trial. It's the work done *before* a trial to make sure the trial can actually happen. This includes: - Patient screening: Identifying wh...
Theripio Innovations (the startup)
Theripio Innovations is the startup company founded by Dr. Christopher Cowan at MUSC to commercialize the MEF2C RNA therapeutic platform. In drug development, when academic researchers develop a promi...
Inpart (Industry Partnering Platform)
Inpart is a global scientific partnering platform used by 90% of the world's top 50 pharmaceutical companies. Think of it as LinkedIn for drug development — it tracks which academic discoveries and te...
MicroRNA Sponge (the "microRNA sponge" mechanism)
In the cell, microRNAs normally act like "volume knobs" — they bind to messenger RNA molecules and turn down (or off) the amount of protein produced. The MUSC team's approach uses synthetic RNAs that ...
MicroRNA Therapeutic Advantage (why MUSC chose RNA over gene therapy)
The MUSC team evaluated multiple approaches (gene therapy, micro-RNA therapeutics) and chose the RNA-based approach because it "offered several advantages." These likely include: - Reversibility: RNA ...
Synthetic Lethality (cancer terminology that appears in CDK2 context)
Synthetic lethality occurs when a cell survives with just ONE gene broken but dies if a SECOND gene is also broken. Cancer drugs exploit this by killing cancer cells (which already have one broken gen...
Phase 1a/b Clinical Trial
What the phases mean:Phase 1a: First-in-human testing. The primary goal is safety: "Is this drug safe in humans at all?" A small group of patients receives escalating doses to find the maximum tolerat...
Variant of Uncertain Significance (VUS)
When genetic testing finds a mutation, sometimes it's unclear whether that mutation causes disease or is just a harmless personal variation. These uncertain results are called Variants of Uncertain Si...
Methylation / DNA Methylation
DNA methylation is an epigenetic process, it doesn't change the DNA sequence itself, but adds chemical "tags" (methyl groups) to the DNA that tell genes to be more or less active. Think of it like hig...
Isogenic (in stem cell research)
"Isogenic" cells are cells that are genetically identical except for one specific difference, like twin siblings where one has a targeted mutation and the other doesn't. Researchers create these by ed...
Natural History Study
A natural history study systematically tracks a disease without giving any treatment. It's like creating a detailed map of a territory before you try to change it. You need to understand the baseline,...
Serotype (AAV Serotype)
AAV isn't a single virus — it's a family of related viruses, each called a serotype. Different serotypes have different tissue preferences. Some are better at reaching the brain, some the liver, some ...
Expression Cassette
In gene therapy, an "expression cassette" is the complete package of genetic instructions packed into the viral vector. It's not just the MEF2C gene itself, it also includes: A promoter (the "start he...
PROTAC (Proteolysis-Targeting Chimaera)
PROTACs are a completely different class of drug from traditional inhibitors. Traditional inhibitors work like a cork in a bottle. They block a protein's function while the drug is present, but wear o...
Blood-Brain Barrier (BBB)
The BBB is an ultra-tight layer of cells lining the brain's blood vessels. Think of it like a super-filter or a nightclub with an extremely strict bouncer. It lets nutrients and oxygen through but blo...
Base Editing
Base editing is a precise gene-editing technique that changes a single DNA letter (like turning an A into a G) without cutting both strands of the DNA helix (which is how traditional CRISPR works). Th...
ctDNA (Circulating Tumor DNA)
Tumors shed tiny fragments of their DNA into the bloodstream. This is "circulating tumor DNA." By measuring ctDNA levels in a blood draw (a "liquid biopsy"), doctors can track cancer without doing tis...
PFS (Progression-Free Survival)
PFS is a common clinical trial metric. It measures how long patients live without their disease getting worse, specifically, without the cancer growing or spreading. It's measured from the start of tr...
iPSC (Induced Pluripotent Stem Cell)
iPSCs are adult cells (like skin cells) that have been reprogrammed back to an embryonic-like state. They can become any cell type in the body. It's like hitting the "reset button" on a fully grown ce...
RNA Therapeutics
RNA is the molecular "messenger" that carries instructions from DNA to the protein-making machinery of the cell. RNA therapeutics work by modifying this messaging process. For MCHS, the MUSC team purs...
AAV (Adeno-Associated Virus)
AAV is a tiny, harmless virus used as a delivery vehicle (sometimes referred to as a "vector") to carry therapeutic genes into cells. Think of it like a Trojan horse. The virus looks normal from the o...
Heterozygous vs Homozygous
...
Germline Mutation
A germline mutation is present in every cell of the body because it was in the original genetic material passed to the embryo. It's different from a "somatic" mutation, which only affects certain cell...
Transcription Factor
Imagine your DNA is a library of instruction manuals (genes). A transcription factor is like a foreman who walks through the library, finds the right manual, and tells the workers: "Okay, start readin...
PSD-95 (DLG4)
PSD-95 (encoded by the DLG4 gene) is a scaffolding protein located at the synapse. It acts like the structural framework of a building, holding receptors, signaling molecules, and other components in ...
CDK4/6 Inhibitor (related to MHS research)
CDK4 and CDK6 are proteins closely related to CDK2. They all work together to drive cell division. CDK4/6 inhibitors (like palbociclib, ribociclib, abemaciclib) are already FDA-approved for breast can...
Retinal (eye) in the context of gene therapy
The retina (the light-sensitive layer at the back of the eye) was actually the first tissue where gene therapy succeeded (Luxturna, 2017). The eye is "immune-privileged" — meaning it doesn't trigger a...
Microdeletion (5q14.3)
A microdeletion is a small chunk of DNA that's been deleted — typically too small to see under a microscope but large enough to remove several genes. "5q14.3" is the specific chromosomal location. It'...
KRAS Mutation and RASopathies
KRAS is one of the most commonly mutated genes in cancer. "RASopathies" are a group of genetic conditions caused by mutations in the RAS signaling pathway (which includes genes like KRAS, BRAF, RAF1, ...
MEF2C-Het (mouse model nomenclature)
"Het" is shorthand for "heterozygous." So Mef2c-Het means mice that have one normal copy of the mouse version of the MEF2C gene (Mef2c, lowercase in mice) and one broken copy. This mirrors the human h...
EpiSign (Methylation Defects testing platform)
EpiSign is a commercial testing platform that analyzes genome-wide DNA methylation patterns to identify disease-specific "epigenetic signatures." It's like a fingerprint — each genetic condition produ...
Epic / Epigenetics (broader concept)
Epigenetics is the study of changes in gene activity that don't involve changes to the DNA sequence itself. Think of your DNA as a piano — the keys (genes) are always there. Epigenetics is like the sh...
Retrospective Study
A retrospective study looks backward in time at existing data — reviewing past patient records, genetic test results, and clinical outcomes to find patterns. It's less rigorous than a prospective stud...
De Novo Mutation
A de novo (Latin for "from new") mutation is a genetic change that occurs for the first time in a person, and it wasn't inherited from either parent. The parents' DNA is normal; the mutation appeared ...
BDNF (Brain-Derived Neurotrophic Factor)
BDNF is a protein that acts like fertilizer for neurons — it promotes neuronal survival, growth, and synaptic plasticity. Without enough BDNF, neurons are fragile and connections between them don't fo...
GRIN2B (NMDA Receptor)
GRIN2B (also known as NR2B) is a subunit of the NMDA-type glutamate receptor, which is critical for synaptic plasticity — the brain's ability to strengthen or weaken connections between neurons based ...
Neurogenesis, Axonogenesis, Synaptogenesis, Dendritogenesis
...
MADS-Box (DNA-binding domain)
The MADS-box is a ~58 amino acid DNA-binding domain — a specific region of the MEF2C protein that acts like a grip or claw that grabs onto specific DNA sequences. It's the part of the protein that lit...
MEF2 (the family, not just MEF2C)
MEF2C is one member of a family of four related transcription factors: MEF2A, MEF2B, MEF2C, and MEF2D. They all share a similar DNA-binding domain (the "MADS-box"), which is why they're grouped togeth...
KRAS and BRAF (signaling pathways in MEF2C context)
KRAS and BRAF are genes that code for proteins in the MAPK/ERK signaling pathway, a cellular "messaging chain" that tells cells to grow, divide, and differentiate. In some cases, mutated KRAS or BRAF ...
NEDHSIL (Neurodevelopmental Disorder with Hypotonia, Stereotypic Hand Movements, and Impaired Language)
NEDHSIL is the alternative name for MEF2C-associated syndrome. It describes the core clinical features without naming the gene. You might see it in older papers or clinical notes. Why the different na...